IGF1R Is a Potential New Therapeutic Target for HGNET-BCOR Brain Tumor Patients.
Antineoplastic Agents
/ pharmacology
Brain Neoplasms
/ drug therapy
DNA Methylation
/ drug effects
Female
Gene Expression Regulation, Neoplastic
/ drug effects
Humans
Insulin-Like Growth Factor II
/ genetics
Male
Molecular Targeted Therapy
Neoplasms, Neuroepithelial
/ drug therapy
Proto-Oncogene Proteins
/ genetics
Pyrimidines
/ pharmacology
Receptor, IGF Type 1
Receptors, Somatomedin
/ genetics
Repressor Proteins
/ genetics
Sulfones
/ pharmacology
Tumor Cells, Cultured
Vinblastine
/ pharmacology
HGNET-BCOR
IGF1R
IGF2
ceritinib
vinblastine
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
21 Jun 2019
21 Jun 2019
Historique:
received:
09
05
2019
revised:
28
05
2019
accepted:
14
06
2019
entrez:
26
6
2019
pubmed:
27
6
2019
medline:
18
12
2019
Statut:
epublish
Résumé
(1)
Identifiants
pubmed: 31234291
pii: ijms20123027
doi: 10.3390/ijms20123027
pmc: PMC6627083
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
BCOR protein, human
0
IGF1R protein, human
0
IGF2 protein, human
0
Proto-Oncogene Proteins
0
Pyrimidines
0
Receptors, Somatomedin
0
Repressor Proteins
0
Sulfones
0
Vinblastine
5V9KLZ54CY
Insulin-Like Growth Factor II
67763-97-7
Receptor, IGF Type 1
EC 2.7.10.1
ceritinib
K418KG2GET
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Oncogene. 1999 Aug 19;18(33):4710-7
pubmed: 10467418
Genes Dev. 2000 Jul 15;14(14):1810-23
pubmed: 10898795
Cancer Res. 2004 Jan 1;64(1):236-42
pubmed: 14729630
Am J Pathol. 2005 Apr;166(4):1153-62
pubmed: 15793295
Mol Cancer Ther. 2006 Apr;5(4):1079-86
pubmed: 16648580
J Biol Chem. 2006 Aug 18;281(33):23785-91
pubmed: 16793764
Cancer Lett. 2007 Dec 18;258(2):155-64
pubmed: 17977647
Cancer Res. 2008 Nov 1;68(21):8788-95
pubmed: 18974121
Br J Cancer. 2008 Dec 2;99(11):1891-9
pubmed: 19034281
Oncologist. 2009 Jan;14(1):83-91
pubmed: 19126579
BMC Res Notes. 2009 Dec 10;2:243
pubmed: 20003239
Pediatr Blood Cancer. 2010 Jul 1;54(7):921-6
pubmed: 20166202
Future Med Chem. 2009 Sep;1(6):1153-71
pubmed: 21425998
J Clin Oncol. 2012 Apr 20;30(12):1358-63
pubmed: 22393086
Crit Rev Oncog. 2013;18(1-2):43-73
pubmed: 23237552
J Med Chem. 2013 Jul 25;56(14):5675-90
pubmed: 23742252
Cell Mol Life Sci. 2014 Jul;71(13):2403-27
pubmed: 24276851
N Engl J Med. 2014 Mar 27;370(13):1189-97
pubmed: 24670165
Proc Natl Acad Sci U S A. 2015 Apr 14;112(15):4678-83
pubmed: 25825734
Pharmacol Res. 2015 Dec;102:200-7
pubmed: 26361725
Nat Commun. 2015 Nov 17;6:8891
pubmed: 26573325
Am J Pathol. 2016 Feb;186(2):435-45
pubmed: 26687816
Cell. 2016 Feb 25;164(5):1060-1072
pubmed: 26919435
Am J Surg Pathol. 2016 Aug;40(8):1009-20
pubmed: 26945340
Cancer Chemother Pharmacol. 2016 Apr;77(4):829-37
pubmed: 26972330
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Oncotarget. 2016 Dec 13;7(50):83378-83391
pubmed: 27825128
Am J Surg Pathol. 2017 Sep;41(9):1254-1260
pubmed: 28704208
Target Oncol. 2017 Oct;12(5):571-597
pubmed: 28815409
Target Oncol. 2017 Dec;12(6):815-826
pubmed: 29067644
Medicine (Baltimore). 2017 Nov;96(45):e8652
pubmed: 29137103
Brain Pathol. 2018 Sep;28(5):710-720
pubmed: 29226988
Oncotarget. 2017 Dec 11;8(69):114210-114225
pubmed: 29371980
Nature. 2018 Mar 22;555(7697):469-474
pubmed: 29539639
World Neurosurg. 2018 Aug;116:279-284
pubmed: 29859355